Profile data is unavailable for this security.
About the company
PT Darya-Varia Laboratoria Tbk is an Indonesia-based pharmaceutical company. Its segments include prescription drugs, consumer health products, export and toll manufacturing services and services. Its consumer health products include skin nutrition, respiratory, vitamins and daily relief. Its prescription products include Daryaven, Urdafalk and Aspilets. Through its multivitamin brands, such as Enervon-C, Enervon Active, Enervon Gold and Supertin, it helps to boost the body's immunity and maintain health. It also provides Imunped as a supplement for kids with Zinc and vitamin C, which are essential for children. Its Forti-D 1000 IU is a health supplement (vitamin) product. Its Fortagyl product provides prevention and treatment of amebiasis, trichomoniasis, giardiasis and post-operation infections. It provides toll manufacturing services for both local and international principals with its two manufacturing facilities: Gunung Putri and Citeureup manufacturing facilities.
- Revenue in IDR (TTM)2.10tn
- Net income in IDR167.53bn
- Incorporated1976
- Employees1.30k
- LocationDarya-Varia Laboratoria Tbk PTLantai 8-10, Talavera Office ParkJl. Letjen T.B. Simatupang Kav. 22-26JAKARTA SELATAN 12430IndonesiaIDN
- Phone+62 2 122768000
- Fax+62 2 122768016
- Websitehttps://www.darya-varia.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apontis Pharma AG | 918.44bn | 14.28bn | 1.75tn | 137.00 | 122.39 | 2.91 | 30.81 | 1.90 | 0.0887 | 0.0887 | 5.70 | 3.72 | 0.9519 | 3.69 | 106.10 | 353,777.10 | 1.48 | -4.10 | 1.77 | -4.68 | 57.16 | 62.47 | 1.55 | -4.23 | 3.37 | -- | 0.00 | -- | 31.12 | 3.90 | 106.67 | -- | 17.38 | -- |
| Oncolys Biopharma Inc | 3.45bn | -234.46bn | 1.75tn | 35.00 | -- | 8.18 | -- | 508.24 | -91.64 | -91.64 | 1.36 | 78.09 | 0.0141 | 0.00 | 0.1464 | 896,685.70 | -95.65 | -54.48 | -106.04 | -62.21 | 0.00 | 41.21 | -6,793.90 | -418.43 | 11.00 | -- | 0.1295 | -- | -50.21 | -52.54 | 13.09 | -- | -3.88 | -- |
| Lee's Pharmaceutical Holdings Ltd | 2.89tn | 192.25bn | 1.76tn | 1.02k | 9.17 | 0.5169 | 4.19 | 0.6099 | 0.1581 | 0.1581 | 2.38 | 2.81 | 0.5083 | 2.21 | 11.40 | 1,369,833.00 | 2.49 | 13.85 | 3.21 | 18.24 | 53.81 | 59.37 | 4.90 | 35.22 | 0.6445 | 8.96 | 0.128 | 2.97 | 32.95 | 2.81 | 457.55 | -5.81 | -10.46 | -4.28 |
| Viromed Medical AG | 0.00 | -4.29bn | 1.81tn | -- | -- | 4.84 | -- | -- | -0.0112 | -0.0112 | 0.00 | 0.9752 | 0.00 | -- | -- | -- | -1.11 | -- | -1.12 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -105.03 | -- | -- | -- |
| Darya-Varia Laboratoria Tbk PT | 2.10tn | 167.53bn | 1.85tn | 1.30k | 11.03 | 1.21 | 8.11 | 0.8802 | 149.58 | 149.58 | 1,874.65 | 1,361.80 | 0.9147 | 2.22 | 2.62 | 1,653,234,000.00 | 7.30 | 7.52 | 10.16 | 10.17 | 53.38 | 52.01 | 7.98 | 7.90 | 1.85 | -- | 0.0006 | 82.63 | 10.40 | 2.86 | 6.70 | -6.78 | 11.73 | 0.5546 |
